The annual meeting of the American Urological Association (AUA) was held May 3-6 in Chicago. Fourteen scientific abstracts featured high-intensity focused ultrasound (HIFU) technology for prostate and kidney applications, with many studies comparing HIFU to other treatment options. One significant highlight was Profound Medical’s presentation of the final data from their TULSA-PRO Ablation Clinical Trial (TACT).
“The interest and attention to ultrasound ablation technologies at this year’s AUA was impressive. Compared to previous meetings, there was a near-exponential increase in attendance, debate, and enthusiasm for incision-free prostate ablation treatments,” said Mathieu Burtnyk, VP Clinical Affairs at Profound Medical. “We were particularly delighted to have the outcomes of our TACT Pivotal Study, designed for registration with the US FDA, presented during the Next Frontier plenary session by Dr. Scott Eggener, Director of the Prostate Cancer Program at University of Chicago Medicine. The response from the clinical community has been very positive, both from physicians who value customized whole-gland treatments, as well as those excited to offer predictable targeted prostate ablations in their practice.”
Focused ultrasound-related abstracts are listed below. The full text for each abstract can be found online in Volume 201, Supplement 4, of the Journal of Urology, published April 1, 2019.
LBA-26 PIVOTAL TRIAL OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) IN MEN WITH LOCALIZED PROSTATE CANCER
MP33-08 PROSTATE CANCER TREATMENT OPTIONS: A CONTEMPORARY WORLDWIDE TREND ANALYSIS
MP67-19 URETHRAL STRICTURE AFTER HIGH-INTENSITY FOCUSED ULTRASOUND
MP78-05 MEDIUM TERM ONCOLOGICAL OUTCOMES IN A LARGE COHORT OF MEN TREATED WITH EITHER FOCAL- OR HEMI-ABALTION WITH HIFU FOR PRIMARY LOCALIZED PROSTATE CANCER
MP78-06 MEDIAN 5-YEAR ONCOLOGICAL OUTCOMES OF SALVAGE HIGH INTENSITY FOCUSED ULTRASOUND FOR PROSTATE CANCER RECURRENCES AFTER PRIMARY RADIOTHERAPY
MP78-08 PREDICTIVE FACTORS OF FAILURE FOLLOWING FOCAL THERAPY FOR PROSTATE CANCER
MP78-10 A COMPARISON OF CANCER CONTROL OUTCOMES AT 5 YEARS OF FOCAL THERAPY (USING HIFU & CRYOTHERAPY) TO RADICAL PROSTATECTOMY FOR CLINICALLY SIGNIFICANT NON-METASTATIC PROSTATE CANCER: PROPENSITY SCORE-MATCHED ANALYSIS
MP78-11 RANDOMIZED CONTROL TRIAL COMPARING FOCAL PROSTATE ABLATION AND RADICAL PROSTATECTOMY IN PATIENTS WITH INTERMEDIATE RISK PROSTATE CANCER. INITIAL EXPERIENCES
MP78-15 CONCOMITANT FOCAL THERAPY AND ROBOTIC LYMPHADENECTOMY IN PROSTATE CANCER: INITIAL SERIES
MP78-16 SALVAGE POSSIBILITIES AFTER FOCAL THERAPY FAILURE: REDO FOCAL TREATMENT VERSUS ROBOTIC RADICAL PROSTATECTOMY ANALYSIS
MP78-18 LONG TERM ONCOLOGICAL OUTCOMES OF CRYOABLATION AND HIFU IN WHOLE GLAND AND FIRST LINE TREATMENT FOR LOCALIZED PROSTATE CANCER
MP78-19 A CONTEMPORARY SYSTEMATIC REVIEW OF PARTIAL PROSTATE GLAND ABLATION OUTCOMES: A COMPARATIVE STUDY OF THERMAL VERSUS NON-THERMAL TECHNOLOGIES
PD26-07 HOW DO ULTRASOUND WAVES CAUSE STONE FRACTURE IN BURST WAVE LITHOTRIPSY?
PD26-08 PRECLINICAL EVALUATION OF BURST WAVE LITHOTRIPSY STONE FRAGMENTATION AND ACUTE SAFETY IN A PORCINE MODEL OF NEPHROLITHIASIS
V05-05 MINIMALLY INVASIVE MANAGEMENT OF RECTOURETHRAL FISTULAS
V08-07 PROSTATE CANCER: USE OF TARGETED BIOPSY INFORMATION FOR PLANNING PARTIAL GLAND ABLATION WITH HIGH-INTENSITY FOCUSED ULTRASOUND